David Lebovitz
Stock Analyst at Citigroup
(3.15)
# 1,070
Out of 4,832 analysts
95
Total ratings
62.5%
Success rate
6.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $59.78 | +30.48% | 4 | May 2, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $266.86 | +31.53% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $295.36 | +58.79% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $30.95 | +139.10% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $45.27 | -16.06% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $46.39 | -63.35% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $99.41 | -7.45% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $56.79 | -4.91% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $32.53 | +7.59% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.54 | +1,003.90% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $0.68 | +1,507.72% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $161.52 | +23.20% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $4.92 | +9,656.10% | 2 | Nov 3, 2020 |
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $59.78
Upside: +30.48%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $266.86
Upside: +31.53%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $295.36
Upside: +58.79%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $30.95
Upside: +139.10%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $45.27
Upside: -16.06%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $46.39
Upside: -63.35%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $99.41
Upside: -7.45%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $56.79
Upside: -4.91%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $32.53
Upside: +7.59%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.54
Upside: +1,003.90%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.68
Upside: +1,507.72%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $161.52
Upside: +23.20%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $4.92
Upside: +9,656.10%